Filing Flows › Heron Therapeutics (HRTX) › Q3 2026
Heron Therapeutics (HRTX) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 9, 2026
Heron Therapeutics (HRTX) reported revenue of $35.2M for the third quarter 2026 (Q3 2026), -8% from a year earlier and -6% from the quarter before. Operating margin was -4.7%, net loss $5.0M (14.2% of revenue).
Heron Therapeutics, Q3 2026: revenue $35.2M (-8% year over year), operating margin -4.7%, net loss $5.0M, operating cash flow −$794K. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $35.2M | -6% | -8% |
| Operating profit | −$1.7M | — | — |
| Net earnings | −$5.0M | — | — |
| Operating cash flow | −$794K | — | -160% |
What changed
Revenue was $35.2M in Q3 2026, down 8% year over year and down 6% from the previous quarter. CINVANTI was the largest line at 57% of revenue. CINVANTI lost $4.0M year over year (down 17%), 134% of the total change.
Gross margin was 74.6%, up 5.8 points from Q3 2025. Operating costs exceeded revenue by $1.7M, an operating margin of -4.7%. Operating expenses fell 8% while revenue fell 8%. The quarter ended with a net loss of $5.0M, narrower than the previous quarter's $5.5M loss. Net interest and other expense of $3.3M was the main reason.
Operating cash flow was −$794K. Non-cash charges added back $391K of depreciation and amortization and $3.1M of share-based compensation. Working capital and other items added $738K. Capital expenditures of $102K exceeded it, leaving free cash flow of −$896K.
Questions
What was Heron Therapeutics' revenue in the third quarter 2026?
Heron Therapeutics (HRTX) reported revenue of $35.2M for the third quarter 2026 (Q3 2026), -8% from a year earlier and -6% from the quarter before.
Was Heron Therapeutics profitable in the third quarter 2026?
Operating loss was $1.7M (-4.7% of revenue) and net loss $5.0M.
Source: Heron Therapeutics 10-Q on SEC EDGAR.